Stock Groups

Eli Lilly Earnings Miss, Revenue Beats In Q3 -Breaking

by Mike Robinson

[ad_1]

© Reuters Eli Lilly Earnings Miss, Revenue Beats In Q3

On Tuesday, Eli Lilly (NYSE 🙂 announced that revenue exceeded expectations and that analysts were wrong about the third quarter.

Eli Lilly declared earnings per share (EPS) of $1.94 on $6.77B in revenue. Investing.com polled analysts and predicted an EPS of $1.96 for $6.64B in revenue.

Eli Lilly shares have risen 45% since the start of the year. However, they are still 11.17% below the 52-week high of $275.87 on August 17. They are outperforming the S&P 500 which is up 21.58% from the start of the year.

Eli Lilly is following other notable earnings from the Healthcare sector this month

Eli Lilly’s report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.

Abbott Labs exceeded expectations by beating all forecasts on October 20, with $1.4 third quarter earnings per share on revenues of $10.93B. This compares to $0.9449 on revenues of $9.56B.

Keep up to date with all the earnings reports coming soon by visiting Investing.com’s earnings calendar

Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.



[ad_2]